Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
CD19-CART for B-cell Malignancies
NCT04184414Phase 1Unknown
- Sponsor
- PersonGen BioTherapeutics
- Start
- Jan 2018
- Primary completion
- Jan 2020
- Modality
- Gene Editing, Gene Silencing, CAR-T Cells
- Countries
- 1
01
Overview
Phase 1, open-label, single-arm trial of anti-CD19 CAR-T cells in B cell acute lymphoblastic leukemia (B-ALL), mantle cell lymphoma (MCL) and follicular lymphoma (FL), sponsored by PersonGen BioTherapeutics. Primary endpoint: Complete Remission at 12 weeks. Status: unknown.
02
Drugs
anti-CD19 CAR-T cells
03
Conditions
B cell acute lymphoblastic leukemia (B-ALL)mantle cell lymphoma (MCL)follicular lymphoma (FL)
Beyond the preview
Go deeper on NCT04184414.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on NCT04184414.